Deuruxolitinib, sold under the brand name Leqselvi, is a medication used for the treatment of

alopecia areata Alopecia areata (AA), also known as spot baldness, is a condition in which hair loss, hair is lost from some or all areas of the body. It often results in a few Baldness, bald spots on the scalp, each about the size of a coin. Psychological st ...

. It is a

Janus kinase inhibitor A Janus kinase inhibitor, also known as JAK inhibitor or jakinib, is a type of immune modulating medication, which inhibits the activity of one or more of the Janus kinase family of enzymes ( JAK1, JAK2, JAK3, TYK2), thereby interfering with ...

selective for JAK1 and

JAK2 Janus kinase 2 (commonly called JAK2) is a non-receptor tyrosine kinase. It is a member of the Janus kinase family and has been implicated in signaling by members of the type II cytokine receptor family (e.g. interferon receptors), the GM-CSF ...

. Although the relative effectiveness of deuruxolitinib and another Janus kinase inhibitor—

baricitinib Baricitinib, sold under the brand name Olumiant among others, is an immunomodulatory medication used for the treatment of rheumatoid arthritis, alopecia areata, and COVID-19. It acts as an inhibitor of janus kinase (JAK), blocking the subty ...

—for alopecia areata may vary depending on the population studied, both drugs are more effective than alternative treatments. Deuruxolitinib was approved for medical use in the United States in July 2024.

Medical uses

Deuruxolitinib is

indicated In medicine, an indication is a valid reason to use a certain test, medication, procedure, or surgery. There can be multiple indications to use a procedure or medication. An indication can commonly be confused with the term diagnosis. A diagnosis ...

for the treatment of adults with severe alopecia areata.

Side effects

The FDA prescribing label for deuruxolitinib contains a

boxed warning In the United States, a boxed warning (sometimes "black box warning", colloquially) is a type of warning that appears near the beginning of the package insert for certain prescription drugs, so called because the U.S. Food and Drug Administratio ...

for serious infections; malignancies; cardiovascular death, myocardial infarction, and stroke; and thrombosis.

Society and culture

Legal status

Deuruxolitinib was approved for medical use in the United States in July 2024.

Names

Deuruxolitinib is the international nonproprietary name and the

United States Adopted Name A United States Adopted Name (USAN) is a unique nonproprietary name assigned to a medication marketed in the United States. Each name is assigned by the USAN Council, which is co-sponsored by the American Medical Association (AMA), the United St ...

References

External links

* * * * {{Authority control Janus kinase inhibitors Pyrrolopyrimidines Pyrazoles Nitriles Cyclopentanes Deuterated compounds